3′-[4-(cyclopentylmethyl)-1H-1,2,3-triazol-1-yl]-3′-deoxythymidine | 1219808-58-8

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: 3′-[4-(cyclopentylmethyl)-1H-1,2,3-triazol-1-yl]-3′-deoxythymidine
• 英文别名: 3'-(4-cyclopentylmethyl-1,2,3-triazol-1-yl)-3'-deoxy-β-D-thymidine；3''-(4-Cyclopentylmethyl-1,2,3-triazol-1-yl)-3''-deoxy-beta-D-thymidine；1-[(2R,4S,5S)-4-[4-(cyclopentylmethyl)triazol-1-yl]-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione
• CAS: 1219808-58-8
• 化学式: C₁₈H₂₅N₅O₄
• 分子量: 375.428
• InChiKey: DXQTXFIMYPXSKO-ARFHVFGLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  110
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  3-环戊基-1-丙炔 、 齐多夫定 在 copper(ll) sulfate pentahydrate 、 sodium ascorbate 作用下， 以 水 、 叔丁醇 为溶剂， 反应 24.25h， 以69%的产率得到3′-[4-(cyclopentylmethyl)-1H-1,2,3-triazol-1-yl]-3′-deoxythymidine
  参考文献：
  名称：

  3′-[4-Aryl-(1,2,3-triazol-1-yl)]-3′-deoxythymidine Analogues as Potent and Selective Inhibitors of Human Mitochondrial Thymidine Kinase

  摘要：

  In an effort to increase the potency and selectivity of earlier identified substrate-based inhibitors of mitochondrial thymidine kinase 2 (TK-2), we now describe the synthesis of new thymidine analogues containing a 4- or 5-substituted 1,2,3-triazol-1-yl substituent at the 3'-position of the 2'-deoxyribofuranosyl ring. These analogues were prepared by Cu- and Ru-catalyzed cycloadditions of 3'-azido-3'-deoxythymidine and the appropriate alkynes, which produced the 1,4- and 1,5-triazoles, respectively. Selected analogues showed nanomolar inhibitory activity for TK-2, while virtually not affecting the TK-1 counterpart. Enzyme kinetics indicated a competitive and uncompetitive inhibition profile against thymidine and the cosubstrate ATP, respectively. This behavior is rationalized by suggesting that the inhibitors occupy the substrate-binding site in a TK-2 ATP complex that maintains the enzyme's active site in a closed conformation through the stabilization of a small lid domain.

  DOI：

  10.1021/jm901532h

文献信息

• NOVEL COMPOUNDS WITH THYMINE SKELETON FOR USE IN MEDICINE
  申请人：TECHNISCHE UNIVERSITÄT DRESDEN

  公开号：US20210130328A1

  公开（公告）日：2021-05-06

  The present invention relates to novel compounds as new chemical entities with thymine skeleton, these compounds for use as in medicine, especially in the treatment of carcinoma, HSP27-associated diseases and cystic fibrosis; and a pharmaceutical product containing at least one of these compounds. Finally, a method of production of that novel compounds is presented. General formula of these compounds is formula (I): as further defined in claim 1.

  本发明涉及一种新型具有胸腺嘧啶骨架的化合物，这些化合物用于医药领域，特别是用于治疗癌症、HSP27相关疾病和囊性纤维化；以及含有至少一种这些化合物的药物产品。最后，提供了一种生产这些新型化合物的方法。这些化合物的一般化学式为式(I)，如权利要求书中进一步定义。
• Thymine derivatives and quinazoline-dione derivatives for the inhibition of HSP27
  申请人：TECHNISCHE UNIVERSITAET DRESDEN

  公开号：US10940150B2

  公开（公告）日：2021-03-09

  The present invention relates to novel HSP27 inhibitors, in particular thymine derivatives according to general formula (VI), (VII) or (VII) and phenothiazine derivatives according to formula (V), and to their use as drugs for the selective inhibition of the heat shock protein HSP27 (HSPB1), in particular for use in the treatment of carcinomas or cystic fibrosis, said inhibitors having a particularly advantageous activity in the lower micromolar or sub-micromolar active ingredient concentration range with respect to HSP27.

  本发明涉及新型HSP27抑制剂，特别是根据通式（VI）、（VII）或（VII）的胸腺嘧啶衍生物和根据式（V）的吩噻嗪衍生物，以及它们作为选择性抑制热休克蛋白HSP27（HSPB1）的药物的用途，特别是用于治疗癌症或囊性纤维化，所述抑制剂在较低的微摩尔或亚微摩尔活性成分浓度范围内对HSP27具有特别有利的活性。
• Compounds with thymine skeleton for use in medicine
  申请人：TECHNISCHE UNIVERSITÄT DRESDEN

  公开号：US11214564B2

  公开（公告）日：2022-01-04

  The present invention relates to novel compounds as new chemical entities with thymine skeleton, these compounds for use as in medicine, especially in the treatment of carcinoma, HSP27-associated diseases and cystic fibrosis; and a pharmaceutical product containing at least one of these compounds. Finally, a method of production of that novel compounds is presented. General formula of these compounds is formula (I): as further defined in claim 1.

  本发明涉及作为具有胸腺嘧啶骨架的新化学实体的新型化合物，这些化合物可用于医药，特别是治疗癌症、HSP27 相关疾病和囊性纤维化；以及含有至少一种这些化合物的医药产品。最后，还介绍了一种生产这种新型化合物的方法。 这些化合物的通式为式（I）： 如权利要求 1 所进一步定义。
• EFFICIENT INHIBITION OF HSP27
  申请人：TECHNISCHE UNIVERSITAET DRESDEN

  公开号：US20170216297A1

  公开（公告）日：2017-08-03

  The present invention relates to novel HSP27 inhibitors, in particular purine derivatives according to general formula (I) or (II) and phenothiazine derivatives according to formula (V), and to their use as drugs for the selective inhibition of the heat shock protein HSP27 (HSPB1), in particular for use in the treatment of carcinomas or cystic fibrosis, said inhibitors having a particularly advantageous activity in the lower micromolar or sub-micromolar active ingredient concentration range with respect to HSP2.
• THYMINE DERIVATIVES AND QUINAZOLINE-DIONE DERIVATIVES FOR THE INHIBITION OF HSP27
  申请人：TECHNISCHE UNIVERSITAET DRESDEN

  公开号：US20180207160A1

  公开（公告）日：2018-07-26

  The present invention relates to novel HSP27 inhibitors, in particular thymine derivatives according to general formula (VI), (VII) or (VII) and phenothiazine derivatives according to formula (V), and to their use as drugs for the selective inhibition of the heat shock protein HSP27 (HSPB1), in particular for use in the treatment of carcinomas or cystic fibrosis, said inhibitors having a particularly advantageous activity in the lower micromolar or sub-micromolar active ingredient concentration range with respect to HSP27.